|
|
Non-resectable slow-growing meningiomas
treated by hydroxyurea
Loven D, Hardoff R, Sever ZB, Steinmetz AP, Gornish M, Rappaport ZH, Fenig E,
Ram Z, Sulkes A
Institute of Oncology, Ha'Emek Medical Center, Afula, Israel.
loven_da@clalit.org.il
Purpose. To test the benefit of hydroxyurea in the treatment of recurrent
and non-resectable slow-growing meningiomas.
Methods. Twelve patients with regrowing non-malignant meningiomas,
were enrolled for a protocol of 2 years with continuous chemotherapy with
hydroxyurea, 20 mg/kg/day.
Response to treatment was evaluated both clinically and by diagnostic imaging
using computed tomography (CT) and 201-Thallium single photon emission CT.
One minimal response was documented by CT, accompanied by clinical
stabilization.
Nine patients showed progressive disease, at least by one imaging procedure,
with a median time to progression of 13 months (range 4-24).
Two other patients were not available for response due to early removal from the
study, following abrupt manifestation of grades 3-4 hematological toxicity.
Conclusion. In this series hydroxyurea has not shown effectiveness in
the treatment of non-resectable slow-growing meningiomas: neither for achieving
response, nor for arresting disease progression.
PMID: 15072471 [PubMed]
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15072471
|
